Stem-cell-derived islets (zimislecel / VX-880)

Type 1 diabetes destroys the insulin-producing islet cells of the pancreas, leaving people dependent on injected insulin for life. Zimislecel (formerly VX-880) aims to replace those lost cells rather than just dose around their absence. Vertex grows fully differentiated, insulin-producing islet cells from pluripotent stem cells — in principle an unlimited, standardized supply — and infuses them as a single dose into the hepatic portal vein (the liver's main blood vessel), where they engraft and secrete insulin in response to blood glucose.¹ Because the cells come from a donor stem-cell line rather than the recipient, this is allogeneic: patients also take chronic immune-suppressing drugs to stop rejection.¹ This makes zimislecel the leading "cell-replacement cure" candidate — an off-the-shelf source of islets, in contrast to therapies limited by scarce deceased-donor pancreases.²

The clinical evidence

The pivotal data come from the FORWARD study (VX-880-101, ClinicalTrials.gov NCT04786262), a Phase 1/2/3 trial whose interim Phase 1/2 results were published in the New England Journal of Medicine in June 2025.¹ In Part A, participants received a half dose; in Parts B and C they received a full single dose of 0.8 billion cells, all with glucocorticoid-free immunosuppression.¹ Among the 14 participants followed at least 12 months, every one had undetectable C-peptide (no own insulin production) at baseline — and after infusion, all showed engraftment and restored insulin production.¹

The results in the 12 fully dosed recipients are striking: all 12 were free of severe hypoglycemic events from day 90 onward, all reached HbA1c below 7%, and all spent more than 70% of the day in the target glucose range of 70-180 mg/dL (3.9-10 mmol/L).¹ Ten of the 12 (83%) were completely off injected insulin at one year,¹ with a mean reduction in daily insulin dose of about 92% across the group.³ Glucose-responsive C-peptide was durable through the full 12 months of follow-up.³ These are the strongest human results yet for stem-cell-derived islets — but the data are interim, short-term and from a small group, so longer-term durability remains to be proven.¹

Eligibility and safety

FORWARD enrolls adults aged 18-65 with type 1 diabetes for more than five years who have impaired awareness of hypoglycemia and a history of severe hypoglycemic events.⁴ The most common serious adverse event was neutropenia (low white-cell counts), in 3 participants.¹ Two deaths occurred — one from cryptococcal meningitis and one from progression of pre-existing dementia — both judged unrelated to zimislecel.¹ The major standing caveat is the need for lifelong immunosuppression, which carries its own risks of infection and toxicity and is why the therapy is restricted to severe cases.¹

Phase and proximity to availability

Zimislecel is now in the pivotal Phase 3 portion of FORWARD, dosing roughly 50 participants.² It holds Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. FDA, PRIME designation from the European Medicines Agency, and an Innovation Passport under the UK MHRA's Innovative Licensing and Access Pathway.² Vertex has stated it expects to submit marketing applications to the FDA, EMA and MHRA in 2026.²

What's coming

If filings proceed on schedule, zimislecel could become the first approved stem-cell-derived islet therapy — but as an immunosuppression-dependent product, its initial use would stay limited to people with the most dangerous hypoglycemia.¹ The real prize is removing the immunosuppression requirement: Vertex is separately advancing encapsulated (device-protected) and gene-edited hypoimmune versions of the same cells designed to evade the immune system without systemic drugs, which would open cell replacement to the broad T1D population.²

References

1. Reichman TW, Markmann JF, Odorico J, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. N Engl J Med (2025);393(9):858-868. According to PubMed. https://doi.org/10.1056/NEJMoa2506549 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

2. Vertex Pharmaceuticals. Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions. Vertex Newsroom (2025). https://news.vrtx.com/news-releases/news-release-details/vertex-presents-positive-data-zimislecel-type-1-diabetes ↩ ↩² ↩³ ↩⁴ ↩⁵

3. Monostra M. Zimislecel, a novel cell therapy, appears to restore islet function in type 1 diabetes. Healio (2025). https://www.healio.com/news/endocrinology/20250621/zimislecel-a-novel-cell-therapy-appears-to-restore-islet-function-in-type-1-diabetes ↩ ↩²

4. A Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Participants With Type 1 Diabetes (FORWARD). ClinicalTrials.gov, NCT04786262 (accessed 2026). https://clinicaltrials.gov/study/NCT04786262 ↩